BioGaia enters new agreements

The two companies have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology.

This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases.

The company has signed a letter of intent agreement with the private US biotech company, Recardio with the objective of combining both companies’ assets and forming a late clinical-stage multi-product cardiovascular-focused specialty care company.

Infex Therapeutics has signed an exclusive license agreement for the Indian market with Indian pharmaceutical company Venus Remedies for the clinical development of its metallo-beta-lactamase-inhibitor MET-X, targeting Gram-negative Enterobacterales.

“We are thrilled to announce this strategic partnership with a top-tier medical school in clinical and radiological research. This is a critical step toward our vision of developing multiple products within data quality and liver disease management,” says Gerald Pötzsch, CEO of ContextVision.

A new agreement has been signed by Norwegian Minister of Health Jan Christian Vestre and German State Secretary Edgar Franke.

Orexo has announced that rights to future transaction proceeds and royalty on future net revenues for the drug candidate vipoglanstat (OX-MPI), have been converted to shares in Gesynta Pharma.